Internal RNA 2'O-methylation in the HIV-1 genome counteracts ISG20 nuclease-mediated antiviral effect.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
11 04 2023
Historique:
accepted: 19 10 2022
revised: 16 09 2022
received: 30 03 2022
medline: 12 4 2023
pubmed: 11 11 2022
entrez: 10 11 2022
Statut: ppublish

Résumé

RNA 2'O-methylation is a 'self' epitranscriptomic modification allowing discrimination between host and pathogen. Indeed, human immunodeficiency virus 1 (HIV-1) induces 2'O-methylation of its genome by recruiting the cellular FTSJ3 methyltransferase, thereby impairing detection by RIG-like receptors. Here, we show that RNA 2'O-methylations interfere with the antiviral activity of interferon-stimulated gene 20-kDa protein (ISG20). Biochemical experiments showed that ISG20-mediated degradation of 2'O-methylated RNA pauses two nucleotides upstream of and at the methylated residue. Structure-function analysis indicated that this inhibition is due to steric clash between ISG20 R53 and D90 residues and the 2'O-methylated nucleotide. We confirmed that hypomethylated HIV-1 genomes produced in FTSJ3-KO cells were more prone to in vitro degradation by ISG20 than those produced in cells expressing FTSJ3. Finally, we found that reverse-transcription of hypomethylated HIV-1 was impaired in T cells by interferon-induced ISG20, demonstrating the direct antagonist effect of 2'O-methylation on ISG20-mediated antiviral activity. Despite highly effective antiretroviral therapies, the human immunodeficiency virus (HIV-1) remains a major public health threat. Its pathogenesis depends on its ability to establish a persistent infection in cells of the immune system. Our study highlights a new insight into how HIV-1 evades early restriction by the immune system. We showed that 2′O-methylation marks found inside HIV-1 RNA promote viral evasion from the antiviral action of the interferon-stimulated gene 20-kDa protein (ISG20), an innate immune restriction factor with a nuclease activity. By disrupting the level of 2′O-methylation of the HIV-1 genome, we demonstrated that ISG20 impairs the reverse transcription process of hypomethylated viruses, as a result of viral RNA decay.

Autres résumés

Type: plain-language-summary (eng)
Despite highly effective antiretroviral therapies, the human immunodeficiency virus (HIV-1) remains a major public health threat. Its pathogenesis depends on its ability to establish a persistent infection in cells of the immune system. Our study highlights a new insight into how HIV-1 evades early restriction by the immune system. We showed that 2′O-methylation marks found inside HIV-1 RNA promote viral evasion from the antiviral action of the interferon-stimulated gene 20-kDa protein (ISG20), an innate immune restriction factor with a nuclease activity. By disrupting the level of 2′O-methylation of the HIV-1 genome, we demonstrated that ISG20 impairs the reverse transcription process of hypomethylated viruses, as a result of viral RNA decay.

Identifiants

pubmed: 36354007
pii: 6819936
doi: 10.1093/nar/gkac996
pmc: PMC10085690
doi:

Substances chimiques

Exoribonucleases EC 3.1.-
Interferons 9008-11-1
ISG20 protein, human EC 3.1.-
RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2501-2515

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Biochemistry. 2001 Jun 19;40(24):7174-9
pubmed: 11401564
Zhonghua Gan Zang Bing Za Zhi. 2013 Jan;21(1):33-7
pubmed: 23663760
RNA Biol. 2021 Oct 15;18(sup1):61-74
pubmed: 34775914
Blood. 1985 Nov;66(5):1149-54
pubmed: 4052630
J Virol. 2007 Dec;81(23):12720-9
pubmed: 17804500
PLoS Pathog. 2016 Mar 24;12(3):e1005478
pubmed: 27010548
Nature. 2013 Feb 7;494(7435):60-4
pubmed: 23334420
Front Immunol. 2021 Jun 28;12:595150
pubmed: 34262555
mSphere. 2018 Sep 19;3(5):
pubmed: 30232164
Immunity. 2005 Aug;23(2):165-75
pubmed: 16111635
Nucleic Acids Res. 2014 Mar;42(5):3228-45
pubmed: 24371270
Cell. 2021 Apr 29;184(9):2394-2411.e16
pubmed: 33743211
Nucleic Acids Res. 2018 Sep 6;46(15):7902-7912
pubmed: 30192980
Mol Ther. 2008 Nov;16(11):1833-40
pubmed: 18797453
Nature. 1990 Jun 7;345(6275):544-7
pubmed: 2348862
PLoS Pathog. 2020 Feb 14;16(2):e1008338
pubmed: 32059034
Nat Commun. 2021 Aug 25;12(1):5113
pubmed: 34433821
J Biol Chem. 2003 May 2;278(18):16151-8
pubmed: 12594219
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Virol. 1995 Nov;69(11):6705-11
pubmed: 7474080
Nat Commun. 2018 Sep 4;9(1):3585
pubmed: 30181559
J Cell Biochem. 2006 Aug 1;98(5):1320-33
pubmed: 16514659
Genes Dev. 1991 Nov;5(11):2108-16
pubmed: 1682219
Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):596-601
pubmed: 26733676
Nucleic Acids Res. 2013 Aug;41(15):7556-65
pubmed: 23771145
PLoS Pathog. 2012;8(4):e1002642
pubmed: 22496660
J Virol. 2010 Aug;84(16):8332-41
pubmed: 20534863
Nature. 2010 Nov 18;468(7322):452-6
pubmed: 21085181
Nucleic Acids Res. 2019 Mar 18;47(5):2681-2698
pubmed: 30726994
RNA Biol. 2017 Jun 3;14(6):680-692
pubmed: 27715451
J Virol. 2017 Feb 14;91(5):
pubmed: 28031359
Curr Opin Virol. 2017 Jun;24:87-96
pubmed: 28527860
Immunity. 2015 Jul 21;43(1):41-51
pubmed: 26187414
Biochemistry. 2014 Apr 1;53(12):1882-98
pubmed: 24617759
Protein Sci. 2021 Jan;30(1):70-82
pubmed: 32881101
Proc Natl Acad Sci U S A. 1981 Jan;78(1):187-91
pubmed: 6264433
Cell. 2013 Jan 17;152(1-2):276-89
pubmed: 23273991
FEBS Lett. 2004 Nov 5;577(1-2):111-6
pubmed: 15527770
Nucleic Acids Res. 2018 Jun 20;46(11):5776-5791
pubmed: 29373715
RNA. 2001 Oct;7(10):1486-95
pubmed: 11680853
Nature. 2017 Jan 19;541(7637):371-375
pubmed: 28002401
Nat Commun. 2015 Nov 09;6:8749
pubmed: 26549102
Methods Mol Biol. 2018;1649:29-48
pubmed: 29130188
Nucleic Acids Res. 2021 Feb 22;49(3):1737-1748
pubmed: 33503246
PLoS Pathog. 2011 May;7(5):e1002059
pubmed: 21637813
Nat Rev Microbiol. 2011 Dec 05;10(1):51-65
pubmed: 22138959
RNA. 2017 Sep;23(9):1329-1337
pubmed: 28576826
Immunity. 2018 Mar 20;48(3):487-499.e5
pubmed: 29525521
PLoS Pathog. 2019 Oct 10;15(10):e1008093
pubmed: 31600344
EMBO J. 2002 Jun 3;21(11):2757-68
pubmed: 12032088
J Gen Virol. 2005 Aug;86(Pt 8):2221-2229
pubmed: 16033969
Nature. 2019 Jan;565(7740):500-504
pubmed: 30626973
J Exp Med. 1997 Jul 7;186(1):139-46
pubmed: 9207008
Antiviral Res. 2013 Sep;99(3):292-300
pubmed: 23769894
Science. 2021 Oct 29;374(6567):eabj3624
pubmed: 34581622
Nucleic Acids Res. 2019 Sep 26;47(17):9282-9295
pubmed: 31340047
J Virol. 2017 Apr 13;91(9):
pubmed: 28250115
J Biol Chem. 1975 Dec 25;250(24):9322-9
pubmed: 1194286
FEBS Open Bio. 2022 Jun;12(6):1096-1111
pubmed: 35174977
Wiley Interdiscip Rev RNA. 2020 May;11(3):e1576
pubmed: 31694072

Auteurs

Priscila El Kazzi (P)

AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France.

Nadia Rabah (N)

AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France.
Université de Toulon, 83130 La Garde, France.

Célia Chamontin (C)

IRIM, CNRS UMR9004, Université de Montpellier, Montpellier, France.

Lina Poulain (L)

AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France.

François Ferron (F)

AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France.
European Virus Bioinformatics Center, Leutragraben 1, 07743 Jena, Germany.

Françoise Debart (F)

IBMM, UMR 5247 CNRS, Université de Montpellier, ENSCM, Montpellier, France.

Bruno Canard (B)

AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France.

Dorothée Missé (D)

MIVEGEC, Univ. Montpellier, CNRS, IRD, Montpellier, France.

Bruno Coutard (B)

Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France.

Sébastien Nisole (S)

IRIM, CNRS UMR9004, Université de Montpellier, Montpellier, France.

Etienne Decroly (E)

AFMB, CNRS, Aix-Marseille University, UMR 7257, Case 925, 163 Avenue de Luminy, 13288 Marseille Cedex 09, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH